PRIMALEUKIN™, commonly known as interleukin-22 (IL-22), has a unique position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from infection and as such has a potential to be targeted against several indications and commanding large market and multiple licensing opportunities. Granted patent has claims protection against all infections in most territories. There are well-validated production methods (human recombinant protein, E. coli or mammalian cell expression) and the regulatory bodies have helped with design of toxicology studies and clinical research. Anticipated toxicity is likely to be low; in animal models the compound has an excellent safety profile. Potent antibacterial activity of IL-22 has been demonstrated in animal models for the important human Gram negative bacteria like Escherichia coli and Klebsiella pneumonia. In addition to activities against Gram negative bacteria, antiviral (against HIV and HCV) and anti-fungal activity (against Candida) have been documented. Moreover, our unpublished data suggest a protective role in respiratory infections. Latest published data suggest that IL-22 is critical to restoration of thymic activity making it an ideal novel target to fight HIV infection and adding strength to using this compound as a broad spectrum protection.
Primaleukin™ is a recombinant human interleukin 22 (IL-22).
Interleukins are soluble proteins which interact with cell surface receptors. They play a key role in cellular signalling to control the immune system.
Primaleukin™ is involved in natural defenses and recovery from infection, initial clinical development target are Gram negative bacteria to be extended to other indications via partnership/collaborations. Patent granted for all infections in most territories
Broad Spectrum Activity (Various Published Studies)
These are all important human pathogens.